Standard BioTools Q4 core revenue $26-27M, seq growth 4-9%; restructuring on track

STANDARD BIOTOOLS INC.

2022-FY EPS reported -$2.43 revenue$97,948,000

Preliminary Q4 core revenue $26-27M (4-9% sequential growth); FY 2022 ~$94-95M.
Restructuring reduces opex >$30M (20%+); headcount cut 15%, real estate 25%.
Targets positive free cash flow by Q4 2024; year-end cash $165M.
Non-GAAP gross margin goal 65-68% by end of 2023; GAAP 52-55%.
Appointed Betsy Jensen CHRO; Hyperion XTi imaging system on track with 2 early units shipped.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

STANDARD BIOTOOLS INC. reported the fiscal year ended December 31, 2022 results: revenue in the range of approximately $94 million–$95 million. Guidance reaffirmed.

Period: the fiscal year ended December 31, 2022
Revenue: in the range of approximately $94 million–$95 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

For the full year, core product and service revenues are expected to be in the range of approximately $94 million–$95 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

STANDARD BIOTOOLS INC. reported the fourth quarter ended December 31, 2022 results: revenue in the range of $26 million–$27 million. Guidance reaffirmed.

Period: the fourth quarter ended December 31, 2022
Revenue: in the range of $26 million–$27 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

For the fourth quarter, core product and service revenues (Genomics and Proteomics excluding discontinued and COVID-19 related products) are expected to be in the range of $26 million–$27 million, representing approximately 4%–9% sequential quarterly growth.

View on SEC.gov

Browse all earnings releases →

STANDARD BIOTOOLS INC. filing history →

Source: SEC EDGAR

accession 0000950142-23-000074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.